Our History
Landmarks in Boehringer Ingelheim UK's History 1900-1965
1939
Testing purity of lactic acid
Product packaging in 1947In the UK, the Cancer Act made it a duty of local authorities to make arrangements for the diagnosis and treatment of cancer.
Albert died and the business was taken over by his two sons, Albert and Ernst and his son-in-law Julius Liebrecht. Research and development continued throughout the Second World War but the production of organic acids was discontinued temporarily.
1955
The corticosteroid prenisalone was developed.
The general economic boom resulted in a dramatic increase in the workforce. New and highly effective drugs were introduced, which formed the basis of the established pillars of Boehringer Ingelheim's research programs: agents for the treatment of respiratory, cardiovascular and gastrointestinal diseases.
Boehringer Ingelheim established a presence in the UK, through a licensing arrangement with pharmaceutical company Pfizer. A field force was developed to establish a sales base and a range of products were introduced.
1957
Clarence Lillehie and Earl Bakk invented the internal pacemaker.
Boehringer Products division began operation. 72 sales representatives began working in the UK and the Republic of Ireland.
1962
New head office in 1962Parting from Pfizer, Boehringer Ingelheim Ltd, was created as the UK product range and turnover continued to grow.